Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...

Sarepta (SRPT) paused shipments of its top-selling gene therapy drug after the US Food and Drug Administration (FDA) raised safety concerns tied to liver toxicity. Yahoo Finance Senior Reporter ...

Q2 2025 Management View Rainer M. Blair, President and CEO, announced a CFO succession plan, stating that "Matt Gugino, the current group CFO of our Life Sciences Innovation Group and Vice President ...

A breakthrough in trade talks with the U.S. might win Ishiba a reprieve, but so far there's been scant sign of progress in negotiating away the threat of higher tariffs on Japan's exports to the U.S.

US stocks remain narrowly mixed amid more earnings reports. Investors are looking for impact of Trump's tariffs. Chip stocks weigh on Nasdaq, S&P 500.